Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy

被引:69
作者
Oseroff, AR
Shieh, S
Frawley, NP
Cheney, R
Blumenson, LE
Pivnich, EK
Bellnier, DA
机构
[1] SUNY Buffalo, Roswell Pk Canc Inst, Dept Dermatol, Buffalo, NY 14263 USA
[2] Dept Pathol, Buffalo, NY USA
[3] Photodynam Therapy Ctr, Buffalo, NY USA
[4] Biostat Consulting Serv, Buffalo, NY USA
[5] Univ Tennessee, Dept Pediat, Memphis, TN USA
[6] Univ Tennessee, Dept Ophthalmol, Memphis, TN USA
关键词
D O I
10.1001/archderm.141.1.60
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To report the use of wide-area 5-aminolevulinic acid photodynamic therapy to treat numerous basal cell carcinomas (BCCs) and basaloid follicular hamartomas (BFHs). Design: Report of cases. Setting: Roswell Park Cancer Institute. Patients: Three children with BCCs and BFHs involving 12% to 25% of their body surface areas. Interventions: Twenty percent 5-aminolevulinic acid was applied to up to 22% of the body surface for 24 hours under occlusion. A dye laser and a lamp illuminated fields up to 7 cm and 16 cm in diameter, respectively; up to 36 fields were treated per session. Main Outcome Measures: Morbidity, patient response, and light dose-photodynamic therapy response relationship and durability. Results: Morbidity was minimal, with selective phototoxicity and rapid healing. After 4 to 7 sessions, with individual areas receiving 1 to 3 treatments, the patients had 85% to 98% overall clearance and excellent cosmetic outcomes without scarring. For laser treatments, a sigmoidal light dose-response relationship predicted more than 85% initial response rates for light doses 150 J/cm(2) or more. Responses,were durable up to 6 years. Conclusion: 5-Aminolevulinic acid photodynamic therapy is safe, well tolerated, and effective for extensive areas of diffuse BCCs and BFHs and appears to be the treatment of choice in children.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 53 条
[1]   Laser-mediated photodynamic therapy of actinic keratoses [J].
Alexiades-Armenakas, MR ;
Geronemus, RG .
ARCHIVES OF DERMATOLOGY, 2003, 139 (10) :1313-1320
[2]   The hedgehog pathway and basal cell carcinomas [J].
Bale, AE ;
Yu, KP .
HUMAN MOLECULAR GENETICS, 2001, 10 (07) :757-762
[3]  
Bellnier D A, 1996, J Clin Laser Med Surg, V14, P311
[4]   SUPERFICIAL PHOTODYNAMIC THERAPY WITH TOPICAL 5-AMINOLEVULINIC ACID FOR SUPERFICIAL PRIMARY AND SECONDARY SKIN-CANCER [J].
CAIRNDUFF, F ;
STRINGER, MR ;
HUDSON, EJ ;
ASH, DV ;
BROWN, SB .
BRITISH JOURNAL OF CANCER, 1994, 69 (03) :605-608
[5]  
CALZAVARAPINTON PG, 1995, J PHOTOCH PHOTOBIO B, V29, P53
[6]   Acrochordons as a presenting sign of nevoid basal cell carcinoma syndrome [J].
Chiritescu, E ;
Maloney, ME .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (05) :789-794
[7]   Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources [J].
Clark, C ;
Bryden, A ;
Dawe, R ;
Moseley, H ;
Ferguson, J ;
Ibbotson, SH .
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2003, 19 (03) :134-141
[8]   Genetic determinants of basal cell carcinoma risk [J].
Epstein, E .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (05) :555-558
[9]  
EVANS FB, 1957, BRIT J CANCER, V64, P959
[10]   PHOTODYNAMIC THERAPY OF EPITHELIAL SKIN TUMORS USING DELTA-AMINOLEVULINIC-ACID AND DESFERRIOXAMINE [J].
FIJAN, S ;
HONIGSMANN, H ;
ORTEL, B .
BRITISH JOURNAL OF DERMATOLOGY, 1995, 133 (02) :282-288